Evestra

What Evestra does

Evestra, Inc. is a privately held, clinical-stage biopharmaceutical company headquartered in Schertz, Texas, with an R&D facility in San Antonio. Founded in 2007–2008 (corporate materials reference 'since 2008'), the company develops products in women's healthcare and oncology based on two proprietary enabling platforms: steroid-based medicinal chemistry and vaginal ring drug delivery technology. Both platforms are supported by an in-house GMP manufacturing capability for active pharmaceutical ingredients and drug products, housed across a 13,000 sq. ft. commercial facility in Schertz and a 7,500 sq. ft. R&D facility in San Antonio. The company also holds a proprietary prodrug platform used in long-acting injectable products.

The pipeline comprises at least seven candidates addressing large unmet needs. Women's health assets include EC625 (a twice-yearly injectable contraceptive developed with Bill and Melinda Gates Foundation support), EC313 (an oral mesoprogestin for endometriosis), EVE132 (vaginal ring for uterine fibroids), EVE135 (vaginal ring for vulvovaginal atrophy), and EVE133 (vaginal ring for overactive bladder). Oncology assets center on EC359, a first-in-class LIF/LIFR inhibitor in development for triple negative breast cancer, ovarian cancer, and pancreatic cancer, along with an orally bioavailable LIF/LIFR antagonist. All products are covered by broad US and international issued patents.

Evestra generates no product revenue and is funded primarily through non-dilutive grants (Gates Foundation $15.9M, NIH $1.5M direct portion of a $3.3M partnership, DoD $960K), supplemented by an undisclosed equity investment from European pharmaceutical partner Gedeon Richter. The commercial model is licensing and royalty-based, with products planned to be commercialized through strategic collaborations with established pharmaceutical companies. Evestra Onkologia, a wholly-owned Polish subsidiary in Lodz launched with European Regional Development Fund support, focuses on oncology assets. The company employs 11–50 people and is led by President and CEO Ze'ev Shaked, Ph.D., with Abigail Kampmann as Executive Chair.

Name

Evestra

Legal name

Evestra, Inc.

Website

https://evestra.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Evestra is a clinical-stage biopharmaceutical company developing women's healthcare and oncology products via proprietary steroid medicinal chemistry and vaginal ring drug delivery platforms, headquartered in Texas with a Polish oncology subsidiary.

Ownership category

akta.pro rank

Product category

Women's Health Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industry

Women’s Health (OTC Gynecologic) (HLAIADAJ)

Keywords

• Women's health pharmaceuticals
• Vaginal drug delivery
• Oncology drug development
• Contraceptive development
• Biopharmaceutical research

Headquarters

HQ city

San Antonio

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Infrastructure

Revenue model

1. Product Development Revenue: Evestra is a clinical-stage biopharmaceutical company. Products are in pre-clinical and clinical stages. The company plans to commercialize through strategic collaborations with established pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Evestra is a clinical-stage biopharmaceutical company developing and commercializing innovative products in women's healthcare and oncology. The portfolio includes pre-clinical and clinical-stage product candidates built on two proprietary technology platforms — steroid medicinal chemistry and vaginal ring drug delivery — and includes long-acting injectable contraceptives, treatments for endometriosis, uterine fibroids, vulvovaginal atrophy, overactive bladder, and first-in-class LIF/LIFR-targeted anticancer drugs. Products are protected by broad US and international patents and supported by in-house GMP manufacturing of APIs and drug products.

Product overview

Evestra is a clinical-stage biopharmaceutical company developing a portfolio of products focused on women's healthcare and oncology. The company's product offerings are based on two enabling technology platforms: medicinal chemistry and vaginal ring drug delivery technology, both supported by GMP manufacturing of APIs and Drug Products. The women's health pipeline includes EC625 (injectable contraceptive), EC313 (oral mesoprogestin for endometriosis), EVE132 (vaginal ring for fibroids), EVE135 (vaginal ring for vulvovaginal atrophy), and EVE133 (vaginal ring for overactive bladder). The oncology pipeline centers on EC359 (injectable LIF/LIFR inhibitor) and an oral LIF/LIFR antagonist for treating Triple Negative Breast Cancer, Ovarian Cancer, and Pancreatic Cancer. All products are protected by broad US and international issued patents.

Differentiator

Problem solved

Functional benefit

Brands

• Evestra Onkologia: Polish biopharmaceutical start-up company focused on oncology and proliferative diseases product development, launched by Evestra, Inc.

Products and services

• EC625

Quantifiable outcome

• LIF and LIFR are expressed in about 80% of human breast cancers
• +3 more outcomes

Segments6 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and major.

• Mays Cancer Center at UT Health San AntoniocoreStrategic or Co-development Partner · 6 September 2022Five-year, $3.3 million NIH Academic Industry Partnership grant awarded September 2022 for research and development of innovative ovarian cancer drug EC359. Evestra co-founded with Texas Biomedical Research Institute. Collaboration includes Dr. Ratna K. Vadlamudi and team studying mechanism, safety and efficacy of EC359.
• Texas Biomedical Research InstitutemajorStrategic or Co-development Partner · 6 September 2022Evestra was co-founded with Texas Biomedical Research Institute. Partnership focused on women's health and oncology research development.
• Evestra OnkologiacoreStrategic or Co-development Partner · 1 January 2022Evestra Onkologia is a Polish biopharmaceutical start-up company located in Lodz, launched by Evestra, Inc. A distinguished team leads them with an impressive record in developing and commercializing innovative oncology and other proliferative diseases products. Evestra Onkologia collaborates with leading Polish research institutions and CRO companies to enhance development and commercialization of innovative assets.
• UT Health San AntoniocoreStrategic or Co-development Partner · 1 January 2022Department of Defense grant for triple negative breast cancer research. Grant proposal 'Targeted Inhibition of Leukemia Inhibitory Factor (LIF/LIFR) Axis for the treatment of triple-negative breast cancer' submitted in collaboration with Dr. Ratna Vadlamudi from UT Health San Antonio. Evestra receives $960,000, UT Health San Antonio receives $761,298 over three years.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• TherapeuticsMD (now Mayne Pharma): TherapeuticsMD was a women's health-focused pharmaceutical company developing branded prescription products in contraception, hormone therapy, and menopause — directly comparable to Evestra's women health pipeline. Recently acquired by Mayne Pharma, illustrating the M&A pathway available to specialized women's health pharma companies.
• Daré Bioscience: Clinical-stage biopharmaceutical company focused on women's health, with candidates in contraception, vaginal health, and sexual health. Direct comparable in stage, therapeutic focus, and reliance on partnerships and non-dilutive capital for advancing a women's health pipeline.
• ObsEva: Clinical-stage biopharmaceutical company developing therapies for women's reproductive health, with a particular focus on endometriosis and uterine fibroids. Closely comparable to Evestra in indication focus (EC313 for endometriosis, EVE132 for fibroids) and clinical-stage profile.
• Agile Therapeutics: Women's health pharmaceutical company focused on contraceptive products, including Twirla (a transdermal contraceptive patch). Comparable to Evestra in contraceptive product development and women's health specialty positioning.
• Gedeon Richter: Hungarian-headquartered European pharmaceutical company with a major women's health franchise (contraception, gynecology). Both an existing equity investor in Evestra and a directly comparable peer in women's health product development.
• Veru Inc. Clinical-stage biopharmaceutical company with two segments — oncology (including breast cancer) and women's health. Comparable to Evestra's dual focus on women's health pharmaceuticals and women's cancer indications.

Broad incumbents

• Organon: Global women's health pharmaceutical company spun off from Merck, with a broad portfolio in contraception, fertility, hormone therapy, and biosimilars. Represents the established incumbent in women's health pharma against which Evestra's pipeline competes.
• Bayer (Pharmaceuticals Division): Major pharmaceutical incumbent with deep women's health franchise in contraception, IUDs (Mirena), and hormone therapy. Relevant as a large competitor and potential partner for Evestra's contraceptive and gynecological product candidates.
• AbbVie: Global pharmaceutical incumbent with leading women's health assets including Orilissa and Lupron for endometriosis. Sets the competitive benchmark for any new entrant in endometriosis and adjacent indications where Evestra's EC313 is positioned.

Emerging players

• Sermonix Pharmaceuticals: Privately held biopharmaceutical company developing targeted therapeutics for women's cancers, particularly breast cancer. Comparable as a smaller, focused oncology player targeting women's health indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/evestra-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evestra